• Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfolios
  • Six-month results from the FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, reveal positive outcomes for treating complex AFib cases
  • New data from the Volt CE Mark Extension Cohort trial for the Volt™ PFA System, demonstrate the strong safety, efficacy and efficiency of treatment of AFib cases for posterior wall ablation
  • Two new conduction system pacing studies showcase initial results of Abbott's investigational UltiSynq™ CSP implantable cardioverter-defibrillator lead and a first-in-human evaluation of the investigational AVEIR™ CSP leadless pacemaker system